SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications-Reference-Cited by-同舟云学术

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

Published:2011-11-08 Issue:5 Volume:26 Page:1137-1140
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Damm F,Thol F,Kosmider O,Kade S,Löffeld P,Dreyfus F,Stamatoullas-Bastard A,Tanguy-Schmidt A,Beyne-Rauzy O,de Botton S,Guerci-Bresler A,Göhring G,Schlegelberger B,Ganser A,Bernard O A,Fontenay M,Heuser M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2011321.pdf

Reference15 articles.

1. Jadersten M, Hellstrom-Lindberg E . Myelodysplastic syndromes: biology and treatment. J Intern Med 2009; 265: 307–328.

2. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289–2301.

3. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788–800.

4. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42: 665–667.

5. Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann M et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010; 95: 1668–1674.

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significance of SF3B1 Mutations in Myeloid Neoplasms;Clinics in Laboratory Medicine;2023-12

2. Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review;Journal of Immunotherapy and Precision Oncology;2022-06-22

3. MicroRNA and Alternative mRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets;Biomedicines;2021-12-02

4. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations;American Journal of Clinical Pathology;2021-05-12

5. Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis;Critical Reviews in Oncology/Hematology;2020-01